AU6740298A - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- AU6740298A AU6740298A AU67402/98A AU6740298A AU6740298A AU 6740298 A AU6740298 A AU 6740298A AU 67402/98 A AU67402/98 A AU 67402/98A AU 6740298 A AU6740298 A AU 6740298A AU 6740298 A AU6740298 A AU 6740298A
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Addiction (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9706089.1A GB9706089D0 (en) | 1997-03-24 | 1997-03-24 | Pharmaceutical composition |
| GB9706089 | 1997-03-24 | ||
| PCT/GB1998/000885 WO1998042344A1 (en) | 1997-03-24 | 1998-03-24 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU6740298A true AU6740298A (en) | 1998-10-20 |
Family
ID=10809779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU67402/98A Abandoned AU6740298A (en) | 1997-03-24 | 1998-03-24 | Pharmaceutical composition |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0969842A1 (en) |
| JP (1) | JP2001518925A (en) |
| AU (1) | AU6740298A (en) |
| GB (1) | GB9706089D0 (en) |
| WO (1) | WO1998042344A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9904911D0 (en) * | 1999-03-03 | 1999-04-28 | Scherer Ltd R P | Pharmaceutical compositions |
| US6268368B1 (en) * | 2000-03-01 | 2001-07-31 | American Pharmaceuticals International | Anionic exchange polymer complexes of buspirone |
| EP1256343B1 (en) * | 2001-05-11 | 2006-07-05 | Jürgen K. Dr. Beck | Flibanserin for the treatment of extrapyramidal movement disorders |
| US8106074B2 (en) | 2001-07-13 | 2012-01-31 | Pierre Fabre Medicament | Pyridin-2-yl-methylamine derivatives for treating opiate dependence |
| ATE424825T1 (en) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | TREATMENT OF HYPERACTIVITY DISORDERS AND ATTENTION DEFICIT |
| US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| DE10138273A1 (en) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Medicines with neuroprotective effects |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| GB0129117D0 (en) * | 2001-12-05 | 2002-01-23 | Glaxo Group Ltd | Pharmaceutical composition |
| US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
| US20050004105A1 (en) * | 2003-01-29 | 2005-01-06 | Emer Leahy | Treatment for a attention-deficit hyperactivity disorder |
| US20070135485A1 (en) * | 2003-10-22 | 2007-06-14 | Gillig James R | Novel mch receptor antagonists |
| AR049478A1 (en) * | 2004-03-25 | 2006-08-09 | Solvay Pharm Bv | A PROCEDURE FOR THE PREPARATION OF 3-AMINO-8- (1-PIPERAZINIL) -2H-1-BENZOPIRAN-2-ONA. SALTS AND HYDRATES AND PHARMACEUTICAL COMPOSITIONS. |
| EP1781292B1 (en) * | 2004-07-15 | 2010-09-22 | Abbott Healthcare Products B.V. | Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one |
| JP2008511569A (en) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | How to treat attention-deficit hyperactivity disorder |
| WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| US20060258640A1 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
| PL1912650T3 (en) | 2005-08-03 | 2018-01-31 | Sprout Pharmaceuticals Inc | Use of flibanserin in the treatment of obesity |
| WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20090023712A1 (en) * | 2006-02-18 | 2009-01-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin |
| EP1988897A1 (en) * | 2006-02-20 | 2008-11-12 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of urinary incontinence |
| US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| EP2026813A2 (en) * | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| JP2009541443A (en) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Flibanserin for the treatment of urinary incontinence and related diseases |
| CA2660476C (en) | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| KR20090045945A (en) | 2006-08-25 | 2009-05-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Controlled Release System and Manufacturing Method Thereof |
| CN1915233B (en) * | 2006-08-30 | 2012-10-03 | 四川科瑞德制药有限公司 | Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation |
| CL2008002693A1 (en) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability |
| US9186359B2 (en) * | 2010-10-15 | 2015-11-17 | Contera Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
| CN113880815B (en) * | 2020-07-03 | 2024-03-29 | 中国药科大学 | Indole derivatives, preparation method and application thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
| US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
| US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| JPS63250318A (en) * | 1987-04-06 | 1988-10-18 | Fujimoto Seiyaku Kk | Pharmaceutical preparation suitable in oral cavity |
| SE8704097D0 (en) * | 1987-10-22 | 1987-10-22 | Astra Ab | ORAL FORMULATION OF BUSPIRONE AND SALTS THEREOF |
| GB8819024D0 (en) * | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
| MC2210A1 (en) * | 1990-06-07 | 1992-11-26 | Wellcome Found | THERAPEUTIC HETEROCYCLIC COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM |
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| JPH04360826A (en) * | 1991-06-07 | 1992-12-14 | Bayer Yakuhin Kk | Controlled release pharmaceutical preparation |
| US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| DE69222006T2 (en) * | 1991-10-30 | 1998-01-22 | Glaxo Group Ltd | Multilayer compositions containing histamine or serotonin antagonists |
| US5246711A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating dysthymia |
| US5246710A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating cyclothymia |
| GB9226530D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
| AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
| DE4319760A1 (en) * | 1993-06-15 | 1994-12-22 | Bayer Ag | Ipsapiron drug preparation |
| GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
| US5698571A (en) * | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
| CA2179678A1 (en) * | 1995-06-23 | 1996-12-24 | Michael Edward Flaugh | 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles |
| KR20000022239A (en) * | 1996-07-11 | 2000-04-25 | 토마스 헤인 | Inclusion complex containing indole selective serotonin agonist |
-
1997
- 1997-03-24 GB GBGB9706089.1A patent/GB9706089D0/en active Pending
-
1998
- 1998-03-24 WO PCT/GB1998/000885 patent/WO1998042344A1/en not_active Ceased
- 1998-03-24 JP JP54523598A patent/JP2001518925A/en not_active Ceased
- 1998-03-24 EP EP98912622A patent/EP0969842A1/en not_active Withdrawn
- 1998-03-24 AU AU67402/98A patent/AU6740298A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0969842A1 (en) | 2000-01-12 |
| WO1998042344A1 (en) | 1998-10-01 |
| JP2001518925A (en) | 2001-10-16 |
| GB9706089D0 (en) | 1997-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6740298A (en) | Pharmaceutical composition | |
| AU4762797A (en) | Pharmaceutical compositions | |
| AU2967597A (en) | Pharmaceutical compositions | |
| AU5387898A (en) | Pharmaceutical agents | |
| AU8107998A (en) | Pharmaceutical compositions | |
| AU4326197A (en) | Pharmaceutical compositions | |
| AU3777897A (en) | Pharmaceutical compositions | |
| AU8591898A (en) | Pharmaceutical compounds | |
| AU7904998A (en) | Pharmaceutical composition containing peptichemio | |
| AU2531295A (en) | Pharmaceutical composition | |
| GB9717444D0 (en) | Pharmaceutical composition | |
| HUP0002455A3 (en) | Gastric-retained pharmaceutical composition | |
| AU9343098A (en) | Pharmaceutical composition | |
| AUPP332898A0 (en) | Pharmaceutical composition | |
| AU1098499A (en) | Emulsifier-lipid composition | |
| AUPN862596A0 (en) | Pharmaceutical compositions | |
| AU4457597A (en) | Pharmaceutical compositions | |
| GB9717770D0 (en) | Pharmaceutical composition | |
| GB2321190B (en) | Pharmaceutical composition | |
| GB9726781D0 (en) | Pharmaceutical composition | |
| AUPO598497A0 (en) | Pharmaceutical composition | |
| AUPO590197A0 (en) | Pharmaceutical composition | |
| AUPO833297A0 (en) | Pharmaceutical compositions | |
| HK1026611A (en) | Pharmaceutical compositions | |
| AUPO597997A0 (en) | Medicinal composition |